[Pharmacological study of amantadine, a new antiparkinson drug].
D000547:Amantadine / Q000494:pharmacology* / Q000627:therapeutic use; D000588:Amines / Q000378:metabolism; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001362:Avoidance Learning / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D006220:Haloperidol; D006801:Humans; D007498:Iris / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology; D051379:Mice; D009068:Movement / Q000187:drug effects; D010095:Oxotremorine; D010546:Perphenazine; D051381:Rats; D013574:Synaptosomes / Q000378:metabolism; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy; D014203:Tremorine
D000588:Amines; D000978:Antiparkinson Agents; D008694:Methamphetamine; D010095:Oxotremorine; D000547:Amantadine; D010546:Perphenazine; D006220:Haloperidol; D014203:Tremorine; D004298:Dopamine